British drug major GSK plc (GSK,GSK.L) announced Wednesday its plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.
The company would make a new $1.2 billion investment in advanced manufacturing facilities and AI and advanced digital technologies, aiming to deliver new, next-generation biopharma factories and laboratories in the country.
The company expects that the new facilities will bridge R&D and manufacturing across both the U.S. and U.K., strengthening the two countries' leadership in life sciences.
According to the firm, the $30 billion investment in the U.S. includes capital investments across GSK's U.S. supply chain, as well as increased investment in R&D drug discovery and development and clinical trial activity.
The U.S. is expected to rank first globally for the number of studies, sites and clinical trials participants conducted by GSK over the next five years, the firm noted.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.